drugset / Trial / NCT01550224
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to first determine if temozolomide plus vorinostat in combination can control relapsed or refractory acute myeloid leukemia (AML) and determine if this combination can be safely taken. The study will look at the side effects of the Temozolomide plus Vorinostat in combination and whether the treatment schedule is tolerated.
Timeline
- Start
- 2013-05-01
- Primary completion
- 2014-11-17
- Completion
- 2014-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Temozolomide | Small molecule | 200 mg/m2 | — |
| Comparator | Vorinostat | Small molecule | 500 mg | Oral |